Effective drug discovery in Chagas disease.
Chagas disease
Trypanosoma cruzi
cure
drug discovery
Journal
Trends in parasitology
ISSN: 1471-5007
Titre abrégé: Trends Parasitol
Pays: England
ID NLM: 100966034
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
24
02
2023
revised:
17
03
2023
accepted:
17
03
2023
medline:
15
5
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
ppublish
Résumé
The Chagas field has gone >50 years without tangible progress toward new therapies. My colleagues and I have recently reported on a benzoxaborole compound that achieves consistent parasitological cure in experimentally infected mice and in naturally infected non-human primates (NHPs). While these results do not assure success in human clinical trials, they significantly de-risk this process and form a strong justification for such trials. Highly effective drug discovery depends on a solid understanding of host and parasite biology and excellent knowledge in designing and validating chemical entities. This opinion piece seeks to provide perspectives on the process that led to the discovery of AN15368, with the hope that this will facilitate the discovery of additional clinical candidates for Chagas disease.
Identifiants
pubmed: 37024318
pii: S1471-4922(23)00076-4
doi: 10.1016/j.pt.2023.03.015
pii:
doi:
Substances chimiques
Trypanocidal Agents
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-431Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The author declares no competing interests.